Lot of talk around NRT and cancer bios
NRT has a dual listing so aggressive US money is able to buy it which is why like GTG it will outperform but I can see what alot are saying at $80m and not even at a clinical stage compared to peers its appears overvalued
PTX to me is the pick of the bunch, unloved and almost hated by the market but with a $4m Mkt Cap $2m in the bank = $2m EV
So its very cheap but thats not what I like, what I like is that unlike most spec Bios it has 2 Phase 2 trials underway (makes it a midstage clinical company) both of which are funded by the US Cancer Council and the US Department of defense
So while it might be an unloved stock the science behind their medicine must have impressed some serious people and jumped over some serious hurdles to warrant that sort of JV funding. Not a DT but the kind of stock which one day could easily be a Disallowed+ from current levels given the very very cheap valuation
GDY could be the start of a break of a vicious down trend needs to double almost to just reach cash backing
Wazza that negative sentiment is why GDY trades at such a large discount to its cash backing but like GBE which traded at a 50% discount to cash when it refocuses into something more sexy like Clean tech (was Graphite for GBE) you will see a big rerating
see June July 2014 for GBE, sure its ended back at its lows but was an awesome trade for me back then from 2.5c to 5c and I left alot on the table as it went almost 3 bags to 7.5c
With a decent clean tech acquisition and 7.5c in cash alone can see GDY pushing 10c
